Phaseline

Targets › NK1R

NK1R (Substance-P receptor): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2027.

Receptor for the tachykinin substance P, also able to bind and respond to tachynins neurokinin A/substance K and neurokinin B/neuromedin-K. The rank order of affinity of this receptor to tachykinins is: substance P > neurokinin A/substance K > neurokinin B/neuromedin-K. Substance P binding to its receptor triggers G protein-coupled receptor signaling via activation of phosphatidylinositol hydrolysis by phospholipase…. (UniProt, P25103)

Open in Phaseline: the race on NK1R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chinese University of Hong KongNetupitant
Neurokinin-1 (NK1) receptor antagonist
NK1RPhase 2Breast CancerDec 2027

Conditions

Breast Cancer (1)

Modalities

small molecule (1)

Companies

Chinese University of Hong Kong (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.